# Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

> **NCT00001131** · NA · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 42 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Aldesleukin
- **DRUG:** HAART

## Key facts

- **NCT ID:** NCT00001131
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2015-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001131, "Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00001131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*